| |
| | Biologic therapies for the treatment of chronic plaque psoriasis - Formulary |
 | | Infliximab is contraindicated in patients with moderate-to-severe (New York Heart Association [NYHA] class III/IV, left ventricular ejection fraction <35%) heart failure (HF), due to the significantly higher incidence of hospitalization and death due to worsening HF symptoms in patients treated with infliximab during clinical trials. |
 | | Two hundred forty-nine patients with plaque-type psoriasis with at least 10% BSA involvement were randomized to receive either infliximab (3 mg/kg [low dose] or 5 mg/kg [high dose]) or placebo by IV infusion at Weeks 0, 2, and 6, followed by assessment at Week 10. |
 | | After 24 weeks of treatment, 25%, 44%, and 59% of patients receiving the low, medium, and high doses of etanercept, respectively, and 33% of those who had initially received placebo (and then crossed over to etanercept), achieved a PASI 75. |
| www.formularyjournal.com /formulary/article/articleDetail.jsp?id=167818 (7495 words) |
|